BTIG Reaffirms Their Buy Rating on Histogenics

In a report issued on May 10, Ryan Zimmerman from BTIG maintained a Buy rating on Histogenics (NASDAQ: HSGX), with a price target of $3.50. The company’s shares closed on Friday at $2.54.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 34.4% and a 63.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and SeaSpine Holdings.

Currently, the analyst consensus on Histogenics is Moderate Buy and the average price target is $3.50, representing a 37.8% upside.

In a report issued on May 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.50 price target.

See today’s analyst top recommended stocks >>

Based on Histogenics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $14.83 million. In comparison, last year the company had a GAAP net loss of $7.08 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions.